Clinical trials: Digestive Disease
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of INCA 0186 in Subjects With Advanced Solid Tumors
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when…
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Trial name
- NCT04989387
- Testing
- INCA00186, Retifanlimab, INCB106385
- Where
- 32 sites in United States, Austria and 4 more
- Volunteers
- 57 people
- Sponsor
- Incyte Corporation
Gastrointestinal Cancer, Pancreatic Cancer
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
The primary objective of this prospective observational study is to characterize the gut and oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients and correlate these findings with cancer…
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT05462314
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Viome
Hepatitis C, Chronic
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the pharmacokinetic interactions between simeprevir and ledipasvir in a treatment regimen consisting of simeprevir (SMV), sofosbuvir (SOF), and ledipasvir (LDV) in treatment-naive…
- Trial name
- NCT02421211
- Testing
- Simeprevir (SMV), Ledipasvir (LDV), Sofosbuvir (SOF)
- Where
- 4 sites in Belgium
- Volunteers
- 41 people
- Sponsor
- Janssen Sciences Ireland UC
Multiple Sclerosis, Colitis, Ulcerative
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
- Trial name
- NCT05131971
- Testing
- GSK3888130B
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colonoscopy, Colorectal Cancer Screening
Robotic Colonoscopy Using the Triton 4.0 System in Adults for Screening, Surveillance, and Diagnosis of Lower Gastrointestinal Conditions
This study is a prospective, single-arm, non-randomized, single site first-in-human study and will be conducted in two phases, where Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening…
- Conditions
- Colonoscopy, Colorectal Cancer Screening, Colorectal Neoplasms, Gastrointestinal Endoscopy
- Trial name
- CARE I (NCT06935734)
- Testing
- Diagnostic Colonoscopy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neptune Medical
Hepatitis C Virus, HIV
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and…
- Trial name
- NCT02073656
- Testing
- LDV/SOF, RBV
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 335 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
- Trial name
- NCT00739453
- Testing
- OSI-906, erlotinib
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Cystic Fibrosis, Pseudomonas Aeruginosa
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic candidate administered…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection
- Trial name
- SWARM-Pa (NCT04596319)
- Testing
- AP-PA02
- Where
- 20 sites in United States
- Volunteers
- 29 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Chronic Hepatitis B
Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B chronic infection.
- Trial name
- CONVERT (NCT01027065)
- Testing
- CYT107+GenHevac+entecavir or tenofovir, CYT107+ entecavir or tenofovir
- Where
- 8 sites in France, Italy
- Volunteers
- 24 people
- Sponsor
- Cytheris SA
Colitis, Ulcerative
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
This is a phase 2, open-label, multicenter study to explore the efficacy and safety of oral GED- 0301 in subjects with active UC, defined as a modified Mayo score (MMS) ≥ 4 and ≤ 9 and a Mayo endoscopic subscore≥ 2.
- Trial name
- NCT02601300
- Testing
- GED-0301
- Where
- 36 sites in United States, Bulgaria and 4 more
- Volunteers
- 41 people
- Sponsor
- Celgene
Ulcerative Colitis
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and…
- Trial name
- NCT00151892
- Testing
- SPD476, Asacol
- Where
- 142 sites in United States, Argentina and 26 more
- Volunteers
- 829 people
- Sponsor
- Shire
Nonalcoholic Steatohepatitis
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group.
- Trial name
- NCT01466894
- Testing
- IMM 124-E
- Sponsor
- Immuron Ltd.
Ulcerative Colitis
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)
- Trial name
- PROTECT-2 (NCT02280629)
- Testing
- LT-02, Mesalamine
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Dr. Falk Pharma GmbH
GERD
Sopran - Omeprazole Treatment Versus Surgery
The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment
- Trial name
- NCT00256737
- Testing
- Omeprazole
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Colonic Neoplasms, Colorectal Neoplasms
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054912
- Testing
- EP2101
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Chronic Hepatitis C
Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
Omega DUROS® is an implantable drug delivery system designed to deliver omega interferon subcutaneously at a constant rate for 90 days.
- Trial name
- NCT00519792
- Testing
- Omega DUROS device
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Intarcia Therapeutics
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
- Trial name
- NCT06657144
- Testing
- CHS-114, Toripalimab, 5 Fluorouracil
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 154 people
- Sponsor
- Coherus Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.